Published in Acta Naturae on May 02, 2017
ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science (2012) 10.42
Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science (2010) 8.04
Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature (2012) 5.47
Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat Neurosci (2010) 5.03
Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat Rev Neurosci (2009) 3.97
Retracted Integrative genomics identifies APOE ε4 effectors in Alzheimer's disease. Nature (2013) 3.35
Brain differences in infants at differential genetic risk for late-onset Alzheimer disease: a cross-sectional imaging study. JAMA Neurol (2014) 3.19
Linking lipids to Alzheimer's disease: cholesterol and beyond. Nat Rev Neurosci (2011) 2.60
A suppressor screen in Mecp2 mutant mice implicates cholesterol metabolism in Rett syndrome. Nat Genet (2013) 2.59
Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: neuropathologic evidence for a mechanism of increased beta-amyloidogenesis. J Neurosci (1997) 2.55
LRRK2 controls an EndoA phosphorylation cycle in synaptic endocytosis. Neuron (2012) 2.49
A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology (2011) 2.35
Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol (1994) 2.25
Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice. Proc Natl Acad Sci U S A (2003) 2.24
The amyloid precursor protein has a flexible transmembrane domain and binds cholesterol. Science (2012) 2.06
Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome. Neuron (2013) 2.00
Aβ(1-42) inhibition of LTP is mediated by a signaling pathway involving caspase-3, Akt1 and GSK-3β. Nat Neurosci (2011) 1.83
Neuronal membrane cholesterol loss enhances amyloid peptide generation. J Cell Biol (2004) 1.66
Liver X receptors in the central nervous system: from lipid homeostasis to neuronal degeneration. Proc Natl Acad Sci U S A (2002) 1.65
Synapses and Alzheimer's disease. Cold Spring Harb Perspect Biol (2012) 1.57
Amyloid beta oligomers (A beta(1-42) globulomer) suppress spontaneous synaptic activity by inhibition of P/Q-type calcium currents. J Neurosci (2008) 1.54
Arc/Arg3.1 regulates an endosomal pathway essential for activity-dependent β-amyloid generation. Cell (2011) 1.52
Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer's disease. J Lipid Res (2003) 1.50
Hippocampal hyperactivation in presymptomatic familial Alzheimer's disease. Ann Neurol (2010) 1.45
Oxysterols: Sources, cellular storage and metabolism, and new insights into their roles in cholesterol homeostasis. Mol Aspects Med (2009) 1.42
Mechanism of amyloid plaque formation suggests an intracellular basis of Abeta pathogenicity. Proc Natl Acad Sci U S A (2010) 1.42
Modeling of presymptomatic and symptomatic stages of parkinsonism in mice. Neuroscience (2011) 1.39
Neuronal LRP1 knockout in adult mice leads to impaired brain lipid metabolism and progressive, age-dependent synapse loss and neurodegeneration. J Neurosci (2010) 1.38
Synaptic activity reduces intraneuronal Abeta, promotes APP transport to synapses, and protects against Abeta-related synaptic alterations. J Neurosci (2009) 1.37
Endogenous amyloid-β is necessary for hippocampal synaptic plasticity and memory. Ann Neurol (2011) 1.35
Reelin signaling antagonizes beta-amyloid at the synapse. Proc Natl Acad Sci U S A (2009) 1.32
Dysregulation of cholesterol balance in the brain: contribution to neurodegenerative diseases. Dis Model Mech (2012) 1.31
High cholesterol content in neurons increases BACE, beta-amyloid, and phosphorylated tau levels in rabbit hippocampus. Exp Neurol (2006) 1.31
Native α-synuclein induces clustering of synaptic-vesicle mimics via binding to phospholipids and synaptobrevin-2/VAMP2. Elife (2013) 1.31
MeCP2 is critical for maintaining mature neuronal networks and global brain anatomy during late stages of postnatal brain development and in the mature adult brain. J Neurosci (2012) 1.25
Statins reduce neuronal alpha-synuclein aggregation in in vitro models of Parkinson's disease. J Neurochem (2008) 1.24
ACAT1 gene ablation increases 24(S)-hydroxycholesterol content in the brain and ameliorates amyloid pathology in mice with AD. Proc Natl Acad Sci U S A (2010) 1.23
Adeno-associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer's disease. Mol Ther (2009) 1.23
Loss of caveolin-1 accelerates neurodegeneration and aging. PLoS One (2010) 1.23
Beta-amyloid causes depletion of synaptic vesicles leading to neurotransmission failure. J Biol Chem (2009) 1.19
Lipid Rafts: Linking Alzheimer's Amyloid-β Production, Aggregation, and Toxicity at Neuronal Membranes. Int J Alzheimers Dis (2010) 1.17
Early presynaptic and postsynaptic calcium signaling abnormalities mask underlying synaptic depression in presymptomatic Alzheimer's disease mice. J Neurosci (2012) 1.16
Severe alterations in lipid composition of frontal cortex lipid rafts from Parkinson's disease and incidental Parkinson's disease. Mol Med (2011) 1.16
Chronic cerebral hypoperfusion accelerates amyloid beta deposition in APPSwInd transgenic mice. Brain Res (2009) 1.13
Quantitative modelling of amyloidogenic processing and its influence by SORLA in Alzheimer's disease. EMBO J (2011) 1.10
Synaptic transmission block by presynaptic injection of oligomeric amyloid beta. Proc Natl Acad Sci U S A (2009) 1.10
Raft disorganization leads to reduced plasmin activity in Alzheimer's disease brains. EMBO Rep (2003) 1.09
Mapping the subcellular distribution of α-synuclein in neurons using genetically encoded probes for correlated light and electron microscopy: implications for Parkinson's disease pathogenesis. J Neurosci (2013) 1.09
Associations between serum cholesterol levels and cerebral amyloidosis. JAMA Neurol (2014) 1.05
Alzheimer disease beta-amyloid activity mimics cholesterol oxidase. J Clin Invest (2005) 1.04
More than cholesterol transporters: lipoprotein receptors in CNS function and neurodegeneration. Neuron (2014) 1.04
Prion protein-mediated toxicity of amyloid-β oligomers requires lipid rafts and the transmembrane LRP1. J Biol Chem (2013) 1.01
Increased cholesterol in Abeta-positive nerve terminals from Alzheimer's disease cortex. Neurobiol Aging (2005) 1.01
Ultrastructural localization of intraneuronal Abeta-peptide in Alzheimer disease brains. J Alzheimers Dis (2007) 1.01
Pivotal role of RanBP9 in integrin-dependent focal adhesion signaling and assembly. FASEB J (2012) 0.99
Markers of cholesterol metabolism in the brain show stronger associations with cerebrovascular disease than Alzheimer's disease. J Alzheimers Dis (2012) 0.95
The novel calpain inhibitor A-705253 potently inhibits oligomeric beta-amyloid-induced dynamin 1 and tau cleavage in hippocampal neurons. Neurochem Int (2008) 0.93
Cellular stress from excitatory neurotransmission contributes to cholesterol loss in hippocampal neurons aging in vitro. Neurobiol Aging (2010) 0.93
Amyloid-β acts as a regulator of neurotransmitter release disrupting the interaction between synaptophysin and VAMP2. PLoS One (2012) 0.92
Down-regulation of seladin-1 increases BACE1 levels and activity through enhanced GGA3 depletion during apoptosis. J Biol Chem (2009) 0.91
Amyloid precursor protein controls cholesterol turnover needed for neuronal activity. EMBO Mol Med (2013) 0.91
Cholesterol loss during glutamate-mediated excitotoxicity. EMBO J (2012) 0.91
ABCA1 influences neuroinflammation and neuronal death. Neurobiol Dis (2013) 0.90
Caveolins: targeting pro-survival signaling in the heart and brain. Front Physiol (2012) 0.89
Evidence for changes in the Alzheimer's disease brain cortical membrane structure mediated by cholesterol. Neurobiol Aging (1992) 0.89
Lipid metabolism and glial lipoproteins in the central nervous system. Biol Pharm Bull (2011) 0.89
Constitutive hippocampal cholesterol loss underlies poor cognition in old rodents. EMBO Mol Med (2014) 0.87
Modeling of autism genetic variations in mice: focusing on synaptic and microcircuit dysfunctions. Dev Neurosci (2012) 0.86
The contribution of inhibitory interneurons to circuit dysfunction in Fragile X Syndrome. Front Cell Neurosci (2014) 0.85
24S-hydroxycholesterol in plasma: a marker of cholesterol turnover in neurodegenerative diseases. Biochimie (2012) 0.85
Improvement of memory deficits and amyloid-β clearance in aged APP23 mice treated with a combination of anti-amyloid-β antibody and LXR agonist. J Alzheimers Dis (2014) 0.84
24(S)-hydroxycholesterol is actively eliminated from neuronal cells by ABCA1. J Neurochem (2013) 0.84
Calcium signaling and neurodegeneration. Acta Naturae (2010) 0.83
Membrane cholesterol enrichment prevents Aβ-induced oxidative stress in Alzheimer's fibroblasts. Neurobiol Aging (2009) 0.83
Atherosclerosis and Alzheimer--diseases with a common cause? Inflammation, oxysterols, vasculature. BMC Geriatr (2014) 0.82
Formation of Toxic Amyloid Fibrils by Amyloid β-Protein on Ganglioside Clusters. Int J Alzheimers Dis (2011) 0.82
Animal models of autism spectrum disorder (ASD): a synaptic-level approach to autistic-like behavior in mice. Exp Anim (2013) 0.82
Plant sterols the better cholesterol in Alzheimer's disease? A mechanistical study. J Neurosci (2013) 0.81
Effects of oxysterols on the blood-brain barrier: implications for Alzheimer's disease. Biochem Biophys Res Commun (2013) 0.81
Cholesterol metabolism and Rett syndrome pathogenesis. Nat Genet (2013) 0.81
LDLR-related protein 10 (LRP10) regulates amyloid precursor protein (APP) trafficking and processing: evidence for a role in Alzheimer's disease. Mol Neurodegener (2012) 0.81
Involvement of endocytosis and alternative splicing in the formation of the pathological process in the early stages of Parkinson's disease. Biomed Res Int (2014) 0.80
Cholesterol levels in fragile X syndrome. Am J Med Genet A (2014) 0.79
Effects of 5α-cholestan-3-one on the synaptic vesicle cycle at the mouse neuromuscular junction. Biochim Biophys Acta (2015) 0.77
Brain Cholesterol Metabolism and Its Defects: Linkage to Neurodegenerative Diseases and Synaptic Dysfunction. Acta Naturae (2016) 0.77
Synaptic aging is associated with mitochondrial dysfunction, reduced antioxidant contents and increased vulnerability to amyloid-β toxicity. Curr Alzheimer Res (2013) 0.77
Plasma membrane injury depends on bilayer lipid composition in Alzheimer's disease. J Alzheimers Dis (2014) 0.77
Long-term atorvastatin treatment leads to alterations in behavior, cognition, and hippocampal biochemistry. Behav Brain Res (2014) 0.76